WEKO3
アイテム
Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia
https://tokushima-u.repo.nii.ac.jp/records/2000246
https://tokushima-u.repo.nii.ac.jp/records/2000246fc9338d6-afff-447f-adf0-1c16efcffdf2
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
dt_14_11_1757.pdf (728 KB)
|
.png)
|
| Item type | 文献 / Documents(1) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2024-11-19 | |||||||||||||||||||||
| アクセス権 | ||||||||||||||||||||||
| アクセス権 | open access | |||||||||||||||||||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||||
| 出版社版DOI | ||||||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||||
| 関連識別子 | https://doi.org/10.1007/s13300-023-01466-6 | |||||||||||||||||||||
| 言語 | ja | |||||||||||||||||||||
| 関連名称 | 10.1007/s13300-023-01466-6 | |||||||||||||||||||||
| 出版タイプ | ||||||||||||||||||||||
| 出版タイプ | VoR | |||||||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||||||||||||||
| タイトル | ||||||||||||||||||||||
| タイトル | Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia | |||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||
| 著者 |
Giménez, Marga
× Giménez, Marga
× Khunti, Kamlesh
× 松久, 宗英
WEKO
415
× Chenji, Suresh
× Syring, Kristen
× Yan, Yu
|
|||||||||||||||||||||
| 抄録 | ||||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||||
| 内容記述 | Introduction: Ready-to-use glucagon represents a significant advancement in the management of severe hypoglycemia for people with diabetes and their caregivers. This indirect treatment comparison (ITC) evaluated the efficacy and safety differences among the three ready-to-use glucagon treatments, Baqsimi® (nasal glucagon), Gvoke® (glucagon injection) and Zegalogue® (dasiglucagon injection), in adults and children with type 1 diabetes (T1D) or type 2 diabetes (T2D). Methods: A systematic literature review was conducted to identify randomized clinical trials assessing the efficacy and safety of Baqsimi, Gvoke or Zegalogue versus reconstituted, injectable glucagon (IG) in reversing insulin-induced hypoglycemia. Bayesian fixed-effect network meta-analysis was used to perform the ITC. Study endpoints included proportion of participants achieving treatment success, maximum blood glucose achieved, time to achieve treatment success and maximum blood glucose and treatment-emergent adverse events (TEAE). Results: Ten clinical trials were included in the ITC (four for Baqsimi, three for Gvoke, and three for Zegalogue). All three treatments achieved high proportions of treatment success (> 98%). In adults, the efficacy results from combined T1D and T2D analysis were consistent with the T1D analysis, except statistically significantly faster in achieving treatment success for Baqsimi vs Gvoke in the combined analysis (13.96 vs 14.66 min). The mean maximum blood glucose values were also statistically significantly lower for Baqsimi (168 mg/dl) vs Gvoke (220 mg/dl) and Zegalogue (190 mg/dl). There was a trend towards a lower number of adults experiencing ≥ 1 TEAE with Baqsimi compared to Gvoke or Zegalogue, but no statistical significance was reached. Conclusion: Baqsimi, Gvoke and Zegalogue had comparable high proportions of treatment success in reversing insulin-induced hypoglycemia. Baqsimi achieved a lower mean maximum blood glucose value, which may have implications for the re-establishment of euglycemia. These findings may help support patients, caregivers and health care providers in their decision-making process when discussing various ready-to-use glucagon treatment options. |
|||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||
| キーワード | ||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||
| 主題 | Baqsimi® | |||||||||||||||||||||
| キーワード | ||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||
| 主題 | Gvoke® | |||||||||||||||||||||
| キーワード | ||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||
| 主題 | Hypoglycemia | |||||||||||||||||||||
| キーワード | ||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||
| 主題 | Indirect treatment comparison | |||||||||||||||||||||
| キーワード | ||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||
| 主題 | Ready-to-use glucagon | |||||||||||||||||||||
| キーワード | ||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||
| 主題 | Type 1 diabetes | |||||||||||||||||||||
| キーワード | ||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||
| 主題 | Type 2 diabetes | |||||||||||||||||||||
| キーワード | ||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||||
| 主題 | Zegalogue® | |||||||||||||||||||||
| 書誌情報 |
en : Diabetes Therapy 巻 14, 号 11, p. 1757-1769, 発行日 2023-09-14 |
|||||||||||||||||||||
| 収録物ID | ||||||||||||||||||||||
| 収録物識別子タイプ | EISSN | |||||||||||||||||||||
| 収録物識別子 | 18696961 | |||||||||||||||||||||
| 収録物ID | ||||||||||||||||||||||
| 収録物識別子タイプ | PISSN | |||||||||||||||||||||
| 収録物識別子 | 18696953 | |||||||||||||||||||||
| 出版者 | ||||||||||||||||||||||
| 出版者 | Springer Nature | |||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||
| 権利情報 | ||||||||||||||||||||||
| 言語 | en | |||||||||||||||||||||
| 権利情報 | This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. | |||||||||||||||||||||
| EID | ||||||||||||||||||||||
| 識別子 | 408898 | |||||||||||||||||||||
| 識別子タイプ | URI | |||||||||||||||||||||
| 言語 | ||||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||||
